Vaccines Against Asymptomatic Sexually Transmitted Diseases

Most sexually transmitted infections cause no symptoms for weeks, months, or years. That silence is the central problem in STI control. A person who feels well has no reason to get tested, no reason to disclose, and no reason to seek treatment, so the infection moves quietly from one partner to the next. The same dynamic applies in pregnancy, where an undiagnosed maternal infection can reach the fetus or newborn. Vaccines change this. Immunization prevents infection before it ever takes hold, which removes the need to detect a disease that announces nothing about itself. The vaccine landscape in 2024 looks very different from a decade ago, with strong tools against some infections, an expanding role for others, and a few high-priority targets that still lack any licensed product.

Why Asymptomatic Infections Are So Hard to Stop

Bacterial infections like chlamydia and gonorrhea are curable with antibiotics, yet most cases go unnoticed. Up to 70 to 80 percent of women with chlamydia have no symptoms, and a large share of men carry it silently as well. Untreated, these infections climb into the upper reproductive tract and cause pelvic inflammatory disease, which the CDC links to ectopic pregnancy, chronic pelvic pain, and infertility. A pregnant woman with untreated chlamydia or gonorrhea can pass the bacteria to her infant during delivery, leading to neonatal conjunctivitis and pneumonia.

Viral infections are equally stealthy. Acute HIV may feel like a mild flu or nothing at all, and during the early window period standard antibody tests can read negative while the person remains highly infectious. Roughly half of adults infected with hepatitis B develop no acute symptoms, and the virus can settle into a chronic course that scars the liver over decades. Herpes simplex virus is asymptomatic or unrecognized in the majority of those who carry it, which is why it spreads so efficiently and also raises the risk of acquiring HIV. Human papillomavirus typically produces no signs whatsoever, and persistent infection with high-risk strains causes nearly all cervical cancer along with many anal, oropharyngeal, and penile cancers.

HPV: The Most Successful STI Vaccine

Gardasil 9 is now the only HPV vaccine available in the United States. The FDA approved it in 2014 CDC, and it protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 16 and 18 alone drive most HPV-related cancers, while 6 and 11 cause the bulk of genital warts. The CDC recommends routine vaccination at age 11 or 12, though the series can begin at 9. Catch-up vaccination is recommended through age 26 for anyone not adequately vaccinated. Adults 27 through 45 may still benefit, and the CDC advises shared decision-making with a clinician in that group, since most older adults have already been exposed to some HPV types.

Dosing depends on age at the first shot. People who start before their 15th birthday need two doses spaced 6 to 12 months apart CDC. Those who begin at 15 or later, or who are immunocompromised, need three doses over six months. The vaccine prevents infection rather than treating an existing one, so it works best when given before any sexual activity. Countries with strong adolescent vaccination programs have already recorded sharp declines in precancerous cervical lesions and warts among vaccinated cohorts.

Hepatitis B: Long-Standing Protection, Now Easier to Get

Hepatitis B has been preventable by vaccine for decades, and the regimen has gotten simpler. The older recombinant vaccines, Engerix-B and Recombivax HB, require three doses over six months and remain widely used, including the universal birth dose given to newborns. Heplisav-B, approved by the FDA in 2017 for adults 18 and older, completes protection in just two doses one month apart. As of 2022, the CDC recommends hepatitis B vaccination for all unvaccinated adults aged 19 through 59, and for adults 60 and older who have risk factors. This expanded the prior risk-based approach, reflecting how many chronic infections trace back to a missed vaccination decades earlier.

Mpox: A Newer Sexually Transmitted Threat

The 2022 global outbreak made clear that mpox spreads through close skin-to-skin contact during sex WHO, with the heaviest burden among gay, bisexual, and other men who have sex with men. The JYNNEOS vaccine, made by Bavarian Nordic and FDA-approved in 2019, is given as a two-dose series 28 days apart. The CDC recommends it for adults at risk of mpox exposure, including people with recent multiple partners, those who attend venues where anonymous sex occurs, and partners of people in these groups. Vaccination is most protective when both doses are completed, and people who received only one dose during the early outbreak are encouraged to return for the second.

Gonorrhea, Herpes, and HIV: Where Research Stands

No vaccine is approved for gonorrhea, but the picture is shifting because Neisseria gonorrhoeae has grown increasingly resistant to the few remaining effective antibiotics. CDC Observational studies, including work published in outlets such as the New England Journal of Medicine, suggest that the meningococcal serogroup B vaccine Bexsero (4CMenB) may offer partial cross-protection against gonorrhea, since its outer-membrane-vesicle antigens overlap with those of the genetically related gonococcus. Trials are ongoing. The CDC does not yet recommend meningococcal B vaccination for gonorrhea prevention, but the possibility has energized a field that long deprioritized vaccines for a curable infection.

There is no licensed vaccine for genital herpes as of 2024. Several earlier candidates failed in clinical trials despite promising early data, a pattern that has frustrated researchers for years. Moderna's mRNA-1608 entered Phase 2 trials, applying the same messenger RNA platform that succeeded against COVID-19, but there is no approval timeline and no guarantee of success. HIV has been the hardest target of all. The virus mutates rapidly and attacks the very immune cells a vaccine would need to recruit, which has defeated decades of candidates. mRNA-based HIV vaccines are in trials, but none is close to approval. The most important recent advance is not a vaccine at all. Lenacapavir, a twice-yearly injection from Gilead, showed 100 percent efficacy at preventing HIV in cisgender women in the 2024 PURPOSE 1 trial. As a long-acting form of pre-exposure prophylaxis, it points toward a future where protection requires only a couple of injections a year.

Vaccines Work Alongside Testing and Treatment

Vaccination does not replace the rest of prevention. Condoms reduce transmission of many infections but offer incomplete protection against pathogens spread by skin contact, including HSV and HPV. Regular STI testing remains essential because no vaccine covers every infection, and several common ones still have none. The strongest protection comes from combining strategies: completing the vaccines you are eligible for, testing on a schedule appropriate to your risk, treating infections promptly, and talking openly with partners. By removing certain threats entirely, vaccines free attention and resources for the infections that still demand vigilance.

Keep exploring on EasySTD: telling recent partners and STD vaccines.